Streetbeat News

Products Services

AVGO

CHTR

CMCSA

Broadcom, Charter Communications, and Comcast are collaborating to develop unified DOCSIS chipsets that support 25Gbps speeds. This partnership aims to enhance internet speed capabilities.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 3:31 pm

CLDX

Celldex Therapeutics shares declined following the announcement of 52-week results from its Barzolvolimab Phase 2 Study in chronic spontaneous urticaria at EADV 2024.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 3:26 pm

BTCUSD

FDX

INTC

MSTR

QQQ

The Federal Reserve cut the fed funds rate by 50bp, impacting inflation and the dollar's purchasing power. Intel restructured its foundry business and secured a $3B government contract. FedEx reported disappointing earnings, supporting the Fed's rate cut decision. Bitcoin is seen as a hedge against inflation, and MicroStrategy continues to invest heavily in it.

Portfolio Pulse from Gary Brode

September 25, 2024 | 3:24 pm

NVDA

Nvidia is expected to produce 450,000 Blackwell AI GPUs in Q4, potentially generating $10 billion in revenue. Despite design issues affecting yields, Nvidia plans to sell these GPUs at a lower price than previous models. The company aims to sell AI server cabinets for higher profitability.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 3:23 pm

CLDX

Celldex Therapeutics' Chief Medical Officer, Diane C. Young, highlights the potential of Barzolvolimab in addressing unmet medical needs. The drug shows profound and sustained results across all study endpoints, indicating its critical role for patients, families, and physicians.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 3:02 pm

CLDX

Celldex Therapeutics has reported safety concerns regarding its drug Barzolvolimab, noting side effects such as hair color changes, neutropenia, hypopigmentation, and nasopharyngitis. These side effects, although mild, could impact patient quality of life. The study shows benefits at 52 weeks but lacks long-term safety data.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 3:01 pm

MU

Micron Technology, Inc. (NASDAQ:MU) is set to release its Q4 earnings, with analysts expecting a significant improvement in earnings and revenue compared to the previous year. The company offers a modest dividend yield of 0.49%, and investors would need a substantial investment to earn $500 monthly from dividends. Micron recently expanded its product line with the Crucial P310 SSD, targeting PCs, laptops, and gaming consoles.

Portfolio Pulse from Avi Kapoor

September 25, 2024 | 2:59 pm

DFSV

PVH

China's Ministry of Commerce is investigating PVH Corp. over alleged discriminatory practices related to Xinjiang cotton, potentially impacting the company's market position. Despite this, PVH shares remain relatively flat, and the company has raised its earnings outlook.

Portfolio Pulse from Nabaparna Bhattacharya

September 25, 2024 | 2:57 pm

CLDX

Celldex Therapeutics presented positive 52-week results from its Phase 2 study of barzolvolimab for chronic spontaneous urticaria, showing 71% of patients achieved complete response. The treatment demonstrated rapid and durable improvement, was well tolerated, and is moving to Phase 3 trials.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 2:47 pm